Oruka Therapeutics (ORKA) COO Lee Sells $42K of Stock

Chief Operating Officer Laura Lee Sandler sold 600 shares of Oruka Therapeutics, Inc. (ORKA) on June 15, 2026. The shares were sold at a price of $69.69, bringing the total value of the transaction to $41,814. This sale was disclosed in a recent filing with the Securities and Exchange Commission and took place on the NasdaqGM exchange.

Cluster of Executive Sales

The sale by Sandler was not an isolated event. On that same Monday, June 15, several other high-ranking leaders at Oruka Therapeutics also sold shares at the identical price of $69.69. Chief Executive Officer Lawrence Otto Klein sold 1,729 shares for roughly $120,494, while General Counsel Paul Quinlan sold 733 shares for about $51,082. Additionally, Arjun Agarwal, the Senior Vice President of Finance, sold 395 shares under a pre-arranged 10b5-1 trading plan. These sales followed a busy week for Agarwal, who had just purchased 9,459 shares on June 12 at $15.87 per share. Later in the year, on October 15, Chief Medical Officer Joana Goncalves also trimmed her stake by selling 7,000 shares at $74.81 each.

Oruka Therapeutics Stock Performance

Shares of Oruka Therapeutics have moved within a wide range over the last year. While the stock hit a high of $115.52, it also dipped as low as $14.89. On the day this article was published, the stock was priced at $68.86. This price is slightly below the $69.69 level where Sandler and the other executives sold their shares in June. The company currently has a market value of about $6.18 billion.

Financial Health and Earnings

Oruka Therapeutics is not yet profitable, which is common for companies in the clinical-stage biotech space. In its most recent financial reports, the company showed a loss of $2.04 per share and a net margin of 0.0%. Despite the lack of current earnings, the company maintains a very high current ratio of 38.51, suggesting it has plenty of cash and short-term assets to cover its immediate bills. The next earnings report is expected on November 11, 2026.

Analysts Set New Price Targets

Wall Street analysts generally have a favorable view of the company's prospects. On September 24, 2024, Wedbush reiterated its Outperform rating with a price target of $165.00. HC Wainwright & Co. also kept a Buy rating on the stock that same day, setting a $120.00 target. Other firms like Guggenheim and BTIG have even higher expectations, with Guggenheim reiterating a Buy rating and a $200.00 price target on August 11, 2026. Across 12 analysts, the consensus is a Strong Buy with an average price target of $155.00.

About Oruka Therapeutics

Oruka Therapeutics is a biotech company based in Menlo Park, California, that develops monoclonal antibodies. Its main focus is finding better treatments for chronic skin conditions like psoriasis and other immunology-related diseases. The company is currently moving several of its lead drug candidates, such as ORKA-001 and ORKA-002, through clinical trials to prove they are safe and effective for patients.

What's Ahead for Oruka Therapeutics, Inc.

Investors often watch insider sales to see how executives view their company's value, though these trades can happen for many personal reasons. The focus for Oruka now shifts to its upcoming phase 2 trial data and its next financial update in November. While these insider reports provide a look at what leadership did in June and October, they are backward-looking and do not necessarily show where the executives stand today.